Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | PKLR | P30613 | 2/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233079 | 0.86 | KMT2A (0.50) | KMT2AMEN1MAPTTP53SLC22A12 | |
| SCHEMBL633646 | 0.77 | KMT2A (0.53) | KMT2AMEN1MAPTTP53SLC22A12 | |
| SCHEMBL15164115 | 0.77 | CYP1A2 (0.34) | — | |
| SCHEMBL2115291 | 0.77 | EGFR (0.43) | KMT2AMEN1PKMCYP2A13GAA | |
| SCHEMBL17208862 | 0.71 | TNKS (0.31) | — | |
| SCHEMBL2115447 | 0.70 | KMT2A (0.54) | KMT2AMEN1MAPTTP53SLC22A12 | |
| SCHEMBL633360 | 0.66 | ALDH1A1 (0.37) | KMT2AMEN1 | |
| SCHEMBL6354523 | 0.65 | P2RX7 (0.82) | KMT2AMAPT | |
| SCHEMBL15177631 | 0.64 | EGFR (0.46) | KMT2AMEN1PKMCYP2A13GAA | |
| SCHEMBL16752419 | 0.64 | SLC22A12 (0.67) | KMT2ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| EP-2419426-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | Glaxo Group Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010118852-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | KMT2A 2219/4885MEN1 564/4885MAPT 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.